Biological Products, (No Diagnostic Substances) — Ranked by Revenue
SIC 2836 · Annual figures from SEC 10-K filings
These rankings show the largest Biological Products, (No Diagnostic Substances) companies by revenue, based on the most recent fiscal year data reported in their annual 10-K filings with the SEC. Only companies with XBRL-tagged financial data are included. Use the tabs below to switch between revenue, net income, and total assets.
| # | Company | Revenue | Fiscal Year |
|---|---|---|---|
| 1 | AMGEN INC AMGN | $36.75B | FY2025 |
| 2 | BIOGEN INC. BIIB | $9.89B | FY2025 |
| 3 | GILEAD SCIENCES, INC. GILD | $5.95B | FY2017 |
| 4 | NEUROCRINE BIOSCIENCES INC NBIX | $2.86B | FY2025 |
| 5 | Moderna, Inc. MRNA | $1.94B | FY2025 |
| 6 | HALOZYME THERAPEUTICS, INC. HALO | $1.40B | FY2025 |
| 7 | NOVAVAX INC NVAX | $1.12B | FY2025 |
| 8 | Tarsus Pharmaceuticals, Inc. TARS | $451.36M | FY2025 |
| 9 | Immunocore Holdings plc IMCR | $400.02M | FY2025 |
| 10 | Krystal Biotech, Inc. KRYS | $389.13M | FY2025 |
| 11 | Adaptive Biotechnologies Corp ADPT | $276.98M | FY2025 |
| 12 | IOVANCE BIOTHERAPEUTICS, INC. IOVA | $263.50M | FY2025 |
| 13 | Vaxart, Inc. VXRT | $237.26M | FY2025 |
| 14 | REGENXBIO Inc. RGNX | $170.44M | FY2025 |
| 15 | Ginkgo Bioworks Holdings, Inc. DNABW | $170.16M | FY2025 |
| 16 | Maze Therapeutics, Inc. MAZE | $167.50M | FY2025 |
| 17 | BIO-TECHNE Corp TECH | $156.58M | FY2017 |
| 18 | Beam Therapeutics Inc. BEAM | $139.74M | FY2025 |
| 19 | Atara Biotherapeutics, Inc. ATRA | $120.77M | FY2025 |
| 20 | AGENUS INC AGEN | $114.20M | FY2025 |
| 21 | ImmunityBio, Inc. IBRX | $113.29M | FY2025 |
| 22 | Century Therapeutics, Inc. IPSC | $109.16M | FY2025 |
| 23 | SUTRO BIOPHARMA, INC. STRO | $102.48M | FY2025 |
| 24 | 4D Molecular Therapeutics, Inc. FDMT | $85.21M | FY2025 |
| 25 | MeiraGTx Holdings plc MGTX | $81.39M | FY2025 |
| 26 | Autolus Therapeutics plc AUTL | $75.39M | FY2025 |
| 27 | RECURSION PHARMACEUTICALS, INC. RXRX | $74.68M | FY2025 |
| 28 | Vir Biotechnology, Inc. VIR | $68.56M | FY2025 |
| 29 | CHAMPIONS ONCOLOGY, INC. CSBR | $56.94M | FY2025 |
| 30 | Invivyd, Inc. IVVD | $53.43M | FY2025 |
| 31 | Protalix BioTherapeutics, Inc. PLX | $52.74M | FY2025 |
| 32 | FENNEC PHARMACEUTICALS INC. FENC | $44.64M | FY2025 |
| 33 | REPLIGEN CORP RGEN | $41.61M | FY2017 |
| 34 | Editas Medicine, Inc. EDIT | $40.52M | FY2025 |
| 35 | Voyager Therapeutics, Inc. VYGR | $40.37M | FY2025 |
| 36 | SANGAMO THERAPEUTICS, INC SGMO | $39.55M | FY2025 |
| 37 | Kymera Therapeutics, Inc. KYMR | $39.21M | FY2025 |
| 38 | C4 Therapeutics, Inc. CCCC | $35.95M | FY2025 |
| 39 | X4 Pharmaceuticals, Inc XFOR | $35.11M | FY2025 |
| 40 | PRECISION BIOSCIENCES INC DTIL | $34.26M | FY2025 |
| 41 | Artiva Biotherapeutics, Inc. ARTV | $32.92M | FY2024 |
| 42 | Scilex Holding Co SCLXW | $30.25M | FY2025 |
| 43 | Metagenomi Therapeutics, Inc. MGX | $25.21M | FY2025 |
| 44 | Vericel Corp VCEL | $23.35M | FY2017 |
| 45 | Arcellx, Inc. ACLX | $22.29M | FY2025 |
| 46 | Alector, Inc. ALEC | $21.05M | FY2025 |
| 47 | LENZ Therapeutics, Inc. LENZ | $19.09M | FY2025 |
| 48 | Pelthos Therapeutics Inc. PTHS | $16.80M | FY2025 |
| 49 | ADMA BIOLOGICS, INC. ADMA | $15.62M | FY2017 |
| 50 | Relay Therapeutics, Inc. RLAY | $15.36M | FY2025 |